• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Dominari Holdings Inc.

    11/10/25 8:03:42 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOMH alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 10-Q

     

    (Mark one)

    ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the quarterly period ended September 30, 2025

     

    or

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from ________to ________

     

    Commission File Number: 001-41845

     

    DOMINARI HOLDINGS INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   52-0849320
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    725 5th Avenue, 23rd Floor, New York, NY 10022
    (Address of principal executive offices and Zip Code)

     

    (212) 393-4540
    (Registrant’s telephone number, including area code)

     

    Not Applicable
    (Former name, former address and former fiscal year, if changed since last report)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock ($0.0001 par value per share)   DOMH   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

     

    As of November 6, 2025 there were 16,012,435 shares of the Company’s common stock issued and outstanding.

     

     

     

     

     

    DOMINARI HOLDINGS INC.

     

    FORM 10-Q

    FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025

     

    TABLE OF CONTENTS

     

        Page
         
    Part I - Financial Information  
         
    Item 1. Financial Statements (Unaudited) 1
         
      Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 1
         
      Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 2
         
      Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 3
         
      Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 5
         
      Notes to the Condensed Consolidated Financial Statements (Unaudited) 6
         
    Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 26
         
    Item 3. Quantitative and Qualitative Disclosures About Market Risk 31
         
    Item 4. Controls and Procedures 31
         
    Part II - Other Information  
         
    Item 1. Legal Proceedings 32
         
    Item 1A. Risk Factors 32
         
    Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32
         
    Item 3. Defaults Upon Senior Securities 32
         
    Item 4. Mine Safety Disclosures 32
         
    Item 5. Other Information 32
         
    Item 6. Exhibits 33
         
    Signatures 34

     

    i

     

    PART I - FINANCIAL INFORMATION

     

    Item 1. Financial Statements

     

    DOMINARI HOLDINGS INC.

    Condensed Consolidated Balance Sheets

    ($ in thousands except share and per share amounts)

     

       September 30,
    2025
       December 31,
    2024
     
       (Unaudited)     
    ASSETS        
    Current assets        
    Cash and cash equivalents  $5,373   $4,079 
    Marketable securities   170,838    5,773 
    Receivable from clearing brokers   28,860    17,279 
    Prepaid expenses and other assets   1,257    1,019 
    Total current assets   206,328    28,150 
               
    Property and equipment, net   161    239 
    Notes receivable, at fair value - non-current portion   
    -
        902 
    Long term equity investments   11,744    12,282 
    Loans to employees   1,868    2,150 
    Right-of-use assets   2,862    2,944 
    Security deposit   483    458 
    Total assets  $223,446   $47,125 
               
    LIABILITIES AND STOCKHOLDERS’ EQUITY          
    Current liabilities          
    Accounts payable and accrued expenses  $779   $919 
    Accrued commissions   4,788    2,057 
    Contract liabilities - current   795    240 
    Lease liability - current   530    410 
    Other current liabilities   599    157 
    Total current liabilities   7,491    3,783 
               
    Lease liability, less current portion   2,464    2,629 
    Contract liabilities, less current portion   3,194    860 
    Total liabilities   13,149    7,272 
               
    Stockholders’ equity          
    Preferred stock, $0.0001 par value, 50,000,000 authorized   
     
        
     
     
    Convertible Preferred Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding as of September 30, 2025 and December 31, 2024; liquidation value of $0.0001 per share   
    -
        
    -
     
    Convertible Preferred Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding as of September 30, 2025 and December 31, 2024; liquidation value of $0.0001 per share   
    -
        
    -
     
    Common stock, $0.0001 par value, 100,000,000 shares authorized; 15,817,323 and 7,037,022 shares issued as of September 30, 2025 and December 31, 2024, respectively 15,817,323 and 6,976,874 shares outstanding as of September 30, 2025 and December 31, 2024   
    -
        
    -
     
    Additional paid-in capital   336,284    263,820 
    Treasury stock, as of cost, 0 shares as of September 30, 2025 and 60,148 as of December 31, 2024   
    -
        (501)
    Accumulated deficit   (126,124)   (223,466)
    Total Dominari stockholders’ equity   210,160    39,853 
    Non-controlling interests   137    
    -
     
    Total stockholders’ equity   210,297    39,853 
    Total liabilities and stockholders’ equity  $223,446   $47,125 

     

    See accompanying notes to unaudited condensed consolidated financial statements.

     

    1

     

    DOMINARI HOLDINGS INC.

    Condensed Consolidated Statements of Operations

    ($ in thousands except share and per share amounts)

    (Unaudited)

     

       Three Months Ended
    September 30,
       Nine Months Ended
    September 30,
     
       2025   2024   2025   2024 
    Revenues  $50,821   $4,043   $93,026   $11,584 
                         
    Operating costs and expenses                    
    General and administrative  $52,420   $7,239   $146,061   $20,321 
    Total operating expenses   52,420    7,239    146,061    20,321 
    Loss from operations   (1,599)   (3,196)   (53,035)   (8,737)
                         
    Other income (expenses)                    
    Interest income   550    280    973    729 
    Gain (loss) on marketable securities, net   159,130    89    163,094    767 
    Realized and unrealized gain (loss) on note receivable, net   
    -
        (429)   221    (2,086)
    Change in carrying  value of investments   (32,000)   (955)   
    -
        (6,445)
    Total other income (expenses)   127,680    (1,015)   164,288    (7,035)
    Net income (loss)  $126,081   $(4,211)  $111,253   $(15,772)
                         
    Less: Net income attributable to non-controlling interests   871    
    -
        1,921    
    -
     
    Net income (loss) attributable to common stockholders of Dominari Holdings Inc.  $125,210   $(4,211)  $109,332   $(15,772)
                         
    Net income (loss) per share, basic and diluted                    
    Basic  $8.11   $(0.67)  $7.98   $(2.57)
    Diluted  $7.27    
    -
       $7.86    
    -
     
                         
    Weighted average number of shares outstanding, basic and diluted                    
    Basic   15,442,342    6,328,261    13,700,375    6,129,504 
    Diluted   17,223,257    
    -
        13,902,950    
    -
     

     

    See accompanying notes to unaudited condensed consolidated financial statements. 

     

    2

     

    DOMINARI HOLDINGS INC.

    Condensed Consolidated Statements of Changes in Stockholders’ Equity

    ($ in thousands except share and per share amounts)

    (Unaudited)

     

    For the Three Months Ended September 30, 2025 and 2024

     

       Preferred Stock   Common Stock  Additional
    Paid-in
       Treasury Stock  Accumulated   Dominari Holding Stockholders’   Non controlling   Total Stockholders’ 
       Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity   Interests   Equity 
    Balance at June 30, 2025   4,659   $
    -
        15,295,930   $
    -
       $334,475    60,148   $(501)  $(246,424)  $87,550    $1,050   $88,600 
    Stock-based compensation   -    
    -
        -         12    -    
    -
        
    -
        12         12 
    Issuance of common stock for cash   -    
    -
        581,541         2,298    -    
    -
        
    -
        2,298         2,298 
    Retirement of treasury stock             (60,148)        (501)   (60,148)   501    
    -
        
    -
             
    -
     
    Dividends Issued                                      (4,910)   (4,910)   
    -
        (4,910)
    Distribution to Non Controlling Interest                                                (1,784)   (1,784)
    Net income   -    
    -
        -    
    -
        
    -
        -    
    -
        125,210    125,210    871    126,081 
    Balance at September 30, 2025   4,659   $
            -
        15,817,323   $
              -
       $336,284          -   $
           -
       $(126,124)  $210,160   $137   $210,297 

     

       Preferred Stock   Common Stock   Additional
    Paid-in
       Treasury Stock   Accumulated   Dominari Holding Stockholders’   Non controlling   Total Stockholders’ 
       Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity   Interests   Equity 
    Balance at June 30, 2024   4,659   $
    -
        6,304,183   $
              -
       $263,184    60,148   $(501)  $(220,324)  $42,359   $
               -
       $42,359 
    Stock-based compensation   -    
    -
        32,103    
    -
        119    -    
    -
        
    -
        119    
    -
        119 
    Net loss   -    
    -
        -    
    -
        
    -
        -    
    -
        (4,211)   (4,211)   
    -
        (4,211)
    Balance at September 30, 2024   4,659   $
            -
        6,336,286   $
    -
       $263,303    60,148   $(501)  $(224,535)  $38,267   $
    -
       $38,267 

     

    See accompanying notes to unaudited condensed consolidated financial statements.

     

    3

     

    For the Nine Months Ended September 30, 2025 and 2024

     

       Preferred Stock  Common Stock  Additional
    Paid-in
       Treasury Stock  Accumulated   Dominari Holding Stockholders’   Non controlling   Total Stockholders’ 
       Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity   Interests   Equity 
    Balance at December 31, 2024   4,659   $
             -
        7,037,022   $
             -
       $263,820    60,148   $(501)  $(223,466)  $39,853   $
             -
       $39,853 
    Stock-based compensation   -    
    -
        1,240,969    
    -
        33,867    -    
    -
        
    -
        33,867    
    -
        33,867 
    Issuance of Common Stock for cash             3,876,054         13,517                   13,517         13,517 
    Issuance of Common Stock from warrants exercised             1,173,426         4,637                   4,637         4,637 
    Shares issued under Advisory Agreements             2,550,000         20,944                   20,944         20,944 
    Retirement of treasury stock             (60,148)        (501)   (60,148)   501                     
                                                            
    Distribution to Non Controlling Interest                                                (1,784)   (1,784)
    Dividends issued                       
    -
                  (11,990)   (11,990)   
    -
        (11,990)
    Net income (loss)   -    
    -
        -    
            -
        
    -
        -    
    -
        109,332    109,332    1,921    111,253 
    Balance at September 30, 2025   4,659   $
    -
        15,817,323   $
    -
       $336,284    -   $
    -
       $(126,124)  $210,160   $137   $210,297 

     

       Preferred Stock  Common Stock  Additional
    Paid-in
       Treasury Stock  Accumulated   Dominari Holding Stockholders’   Non controlling   Total Stockholders’ 
       Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity   Interests   Equity 
    Balance at December 31, 2023   4,659   $
    -
        5,995,065   $
    -
       $262,187    60,148   $(501)  $(208,763)  $52,923   $
    -
       $52,923 
    Stock-based compensation   -    
    -
        341,221    
    -
        1,116    -    
    -
        
    -
        1,116    
    -
        1,116 
    Net loss   -    
    -
        -    
    -
        
    -
        -    
    -
        (15,772)   (15,772)   
    -
        (15,772)
    Balance at September 30, 2024   4,659   $
    -
        6,336,286   $
    -
       $263,303    60,148   $(501)  $(224,535)  $38,267   $
    -
       $38,267 

     

    See accompanying notes to unaudited condensed consolidated financial statements.

     

    4

     

    DOMINARI HOLDINGS INC.

    Condensed Consolidated Statements of Cash Flows

    ($ in thousands)

    (Unaudited)

     

       Nine Months Ended
    September 30,
       2025   2024 
    Cash flows from operating activities        
    Net income/(loss)   111,253   $(15,772)
    Adjustments to reconcile net income/ (loss) to net cash used in operating activities:          
    Amortization of right-of-use assets   309    287 
    Depreciation   78    79 
    Unrealized (gain) loss on marketable securities   (163,685)   3,361 
    Change in carrying value of long-term equity investments   
    -
        6,445 
    Non-cash underwriting revenue   (17,909)   
    -
     
    Non-cash commissions expense   16,651    
    -
     
    Stock-based compensation   54,811    1,116 
    Realized loss (gain) on marketable securities   897    (3,762)
    Realized and unrealized (gain) loss on note receivable   (221)   2,086 
    Changes in operating assets and liabilities:          
    Prepaid expenses and other assets   (238)   165 
    Receivable from clearing brokers   (11,581)   (6,494)
    Security Deposits   (25)     
    Accounts payable and accrued expenses   (140)   257 
    Accrued salaries and benefits   
    -
        (38)
    Accrued commissions   2,731    295 
    Lease liabilities   (272)   (299)
    Contract liabilities   2,889    
    -
     
    Other current liabilities   442    314 
    Notes receivable, at fair value - net interest accrued   (21)   58 
    Net cash (used in) operating activities   (4,031)   (11,902)
               
    Cash flows from investing activities          
    Purchase of marketable securities   (16,960)   (4,007)
    Sale of marketable securities   15,941    14,767 
    Collection of principal on note receivable   1,144    750 
    Loans to employees   
    -
        (2,390)
    Collection of loans to employees   282    2 
    Purchase of long-term investments   
    -
        (150)
    Sale of long term investments   538    3,500 
               
    Net cash provided by investing activities   945    12,472 
               
    Cash flows from financing activities          
    Cash paid for dividends   (11,990)   
    -
     
    Distribution to Non Controlling Interest   (1,784)   
    -
     
    Cash received from issuance of common stock   13,517    
    -
     
    Cash received from issuance of common stock for warrants exercised   4,637    
    -
     
    Net cash provided by financing activities   4,380    
    -
     
               
    Net increase in cash and cash equivalents and restricted cash   1,294    570 
    Cash and cash equivalents, beginning of period   4,079    2,833 
               
    Cash and cash equivalents, end of period  $5,373   $3,403 

     

     See accompanying notes to unaudited condensed consolidated financial statements.

     

    5

     

    DOMINARI HOLDINGS INC.

    Notes to Condensed Consolidated Financial Statements

    (Unaudited)

     

    Note 1. Organization and Description of Business and Recent Developments

     

    Organization and Description of Business

     

    Dominari Holdings Inc. (the “Company”), formerly Aikido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Dominari Labs, LLC (formerly Aikido Labs, LLC). In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker- dealer, a member of the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities is also licensed to provide investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

     

    On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer, a member of FINRA and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). The registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financials’ acquisition of FPS’ Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.

     

    On October 13, 2023, the Company entered into two separate Limited Liability Agreements with Dominari Manager LLC (“Manager”) and Dominari IM LLC (“Investment Manager”), which are both wholly owned subsidiaries and whose operations are included within the unaudited condensed consolidated financial statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

     

    On May 21, 2024, Dominari Financial and Heritage Strategies LLC (“HS”) entered into a Limited Liability Company Operating Agreement (the “JV Agreement”) of Dominari Financial Heritage Strategies LLC (“DFHS”). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominari Financial and HS are the co-managing members (the “Co-Managing Members”), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement.

     

    6

     

    On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”). The Company holds a ninety percent (90%) Membership Interest in each, and their operations are included within the unaudited condensed consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

     

    Note 2. Liquidity and Capital Resources

     

    The Company monitors its liquidity position on a regular basis. The Company continues to incur significant ongoing administrative and other expenses, including public company expenses, while the Company continues to implement its business strategy. The Company intends to fund its activities through cash flows from investments and financing activities along with managing current cash on hand and other liquid assets. As of September 30, 2025, the Company has approximately $5.4 million of cash and cash equivalents and $170.8 million of marketable securities. Included in marketable securities is $156.4 million related to American Bitcoin shares that is subject to a lock-up period until March 1, 2026 ( See Note 5) along with approximately $1.2 million of marketable securities that are subject to lock-up periods that will end in November 2025 and another $4.0 million of marketable securities with lock-up periods that will end by March 1, 2026 as well. Additionally, the Company had approximately $28.9 million in receivable from clearing brokers. Unless otherwise noted, all such funds are available to fund the Company’s operations. Additionally, the Company’s working capital balance at September 30, 2025, totaled $198.8 million. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

     

    Note 3. Summary of Significant Accounting Policies

     

    There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2024 Annual Report.

     

    Basis of Presentation and Principles of Consolidation

     

    The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of September 30, 2025, condensed consolidated statements of operations for the three and nine months ended September 30, 2025 and 2024, condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2025 and 2024, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2025 and 2024 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September 30, 2025 are not necessarily indicative of results to be expected for the year ending December 31, 2025 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2024 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2024.

     

    The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial Inc., Dominari IM LLC, Dominari Manager LLC and Dominari Securities along with American Ventures IM LLC and American Ventures Manager LLC, both of which are owned 90% by the Company. All significant intercompany balances and transactions have been eliminated in consolidation.

     

    7

     

    Joint Ventures

     

    On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its unaudited condensed consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of September 30, 2025, there has been no material activity in DFHS.

     

    Use of Estimates

     

    The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable, valuation of non-cash consideration received, and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

     

    Receivable from Clearing Brokers

     

    Receivable from Dominari Securities’ clearing brokers totaling $28.9 million consisted of approximately $23.9 million of liquid insured deposits, $4.5 million of commissions receivable, and $0.5 million in good faith deposits maintained by the Company with its clearing brokers as of September 30, 2025. Receivable from Dominari Securities’ clearing brokers consisted of approximately $15.4 million of liquid insured deposits, $1.3 million of commissions receivable and $0.6 million of good faith deposits maintained by the Company with its clearing brokers as of December 31, 2024. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer creditworthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of September 30, 2025 and December 31, 2024 an allowance for credit losses was not deemed necessary.

     

    Leases

     

    The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases).

     

    8

     

    Revenue

     

    The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

     

    The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

     

    ●Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606 and expenses these costs immediately, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.

     

    Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized. Similarly, any commissions or compensation expense from providing non-cash consideration provided to employees as is recognized at fair value in accordance with ASC 820 on the same date.

     

    ●Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying unaudited condensed consolidated balance sheet.

     

    ●Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:

     

    ●The Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. In determining the transaction price, an entity may include variable consideration only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur, or when the uncertainty associated with the variable consideration is resolved. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.

     

    ●Management fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, and subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.

     

    9

     

    ●Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management services. As of September 30, 2025, the Company recognized $4.0 million of contract liabilities of which $0.8 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2030. As of December 31, 2024, the Company recognized $1.1 million of contract liabilities of which $0.2 million was expected to be recognized within a year. The remaining balance is expected to be recognized through 2030. During the nine months ended September 30, 2025, the Company recognized revenue of $0.3 million that was included in contract liabilities as of December 31, 2024. During the three months ended September 30, 2025, the Company recognized revenue of $0.2 million that was included in contract liabilities as of December 31, 2024. There was no revenue associated with contract liabilities recognized during the period ended September 30, 2024.

     

    ●Carried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high-water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved.  Carried Interest Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to claw back or reversal. During the nine months ended September 30, 2025, the Company recognized carried interest of $19.2 million.

     

    ●Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b-1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.

     

    Long-term equity investments

     

    The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying unaudited condensed consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

     

    Warrant Investments

     

    Warrant fair values are primarily determined using a Black Scholes option pricing model, which include the underlying stock price, warrant strike price, expected remaining term, volatility, and risk-free rate as the primary inputs to the model. Increases or decreases in any of these inputs could result in a material change in fair value. Additionally, for warrants that have periods of contractual trading restrictions, marketability discounts were considered in determining fair value.

     

    ●The underlying stock price is equal to the closing price of the underlying stock as of the measurement date.

     

    ●The expected remaining term is equal to the time to expiration of the warrant investment.

     

    ●Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant investment price.

     

    ●The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining term of the warrant investment.

     

    ●Marketability discounts are applied for warrants that have sales restrictions (or lock up periods). These discounts are calculated using a combination of the Finnerty Model and the Asian Put Model using a term equal to the period of such restriction.

     

    Recently adopted accounting standards

     

    In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The standard requires all entities subject to income taxes to disclose disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The new requirement is effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its unaudited condensed consolidated financial statements.

     

    In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity discloses more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its unaudited condensed consolidated financial statements.

     

    10

     

    Effect of new accounting pronouncements to be adopted in future periods

     

    The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

     

    Note 4. Marketable Securities

     

    The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and nine months ended September 30, 2025 and 2024, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

     

       Three Months Ended
    September 30,
       Nine Months Ended
    September 30,
     
       2025   2024   2025   2024 
    Realized gain (loss)  $517   $432   $(897)  $3,762 
    Unrealized gain (loss)   158,500    (421)   163,685    (3,361)
    Dividend income   113    78    306    366 
    Total  $159,130   $89   $163,094   $767 

     

    The unrealized gain for the three and nine months ended September 30, 2025, includes an unrealized gain of $156.4 million from the Company’s investment in American Bitcoin Corp. (“ABTC”). During prior quarters in 2025, the Company’s investment in ABTC was included within the long-term equity investments caption of the unaudited condensed consolidated balance sheet. In September 2025, ABTC became publicly listed on the Nasdaq (Ticker: ABTC) and accordingly, the Company’s investment in ABTC was reclassified to marketable securities. Refer to Note 5 “Long Term Equity Investments” for additional information regarding ABTC.

     

    Note 5. Long Term Equity Investments

     

    The Company holds interests in several privately held companies as long-term investments. The following table presents the Company’s long-term investments as of September 30, 2025, and December 31, 2024 ($ in thousands):

     

       December 31, 2024   September 30, 2025 
       Cost
    Basis
       Carrying
    Value
       Cost
    Basis
       Carrying
    Value
     
    Investment in Kerna Health  $2,140   $4,940   $2,140   $4,940 
    Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*   1,000    1,000    1,000    1,000 
    Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a. Masterclass)*   170    170    170    170 
    Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a. Kraken)**   597    364    597    364 
    Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*   3,500    2,248    3,500    2,248 
    Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.) **   1,240    1,240    1,240    1,240 
    Investment in Aeon Partners Fund Series DB (Databricks, Inc.)*   716    538    
    -
        
    -
     
    Investment in Discord Inc.   476    476    476    476 
    Investment in Thrasio, Inc.   300    
    -
        300    
    -
     
    Investment in Automation Anywhere, Inc.   476    397    476    397 
    Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*   100    109    100    109 
    Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*   25    25    25    25 
    Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*   25    25    25    25 
    Investment in AdvEn Inc.   750    750    750    750 
                         
    Total  $11,515   $12,282   $10,799   $11,744 

     

    *Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

     

    **Investments made in these companies are through both an SPV and direct investments.

     

    11

     

    The Company recorded a $32.0 million decrease to the carrying value for the three-month period ended September 30, 2025 as a result of the reclassification of the ABTC investment to marketable securities and no change for the nine months ended September 30, 2025. The Company recorded a decrease of approximately $0.9 million. for the three months ended September 30, 2024 and a decrease of approximately $6.5 million for the nine-month period ended September 30, 2024.

     

    Investment in Aeon Partners Fund Series DB (Databricks, Inc.)

     

    During the first quarter of 2025, the Company redeemed its interest in Databricks, Inc. for net proceeds of approximately $0.5 million, which resulted in a gain of approximately $28,000.

     

    Investment in American Bitcoin Corp.

     

    On February 18, 2025, the Company announced the creation of American Data Centers Inc. (“ADC”), a strategic venture focused on acquiring, building out and transforming data center campuses across the United States to meet the accelerated demand for advanced computing.

     

    On March 31, 2025, ADC completed a series of transactions (“Transactions”), wherein ADC, Hut 8 Corp., a Delaware corporation, and certain of its subsidiaries (“Hut 8”), contributed to ADC substantially all of Hut 8’s wholly owned ASIC bitcoin miners in exchange for newly issued stock representing 80% of the issued and outstanding equity interests of ADC. At the closing of the Transactions, ADC changed its name to American Bitcoin Corp. (“American Bitcoin”). In connection with the Transactions, American Bitcoin and Hut 8 entered into definitive agreements for Hut 8 to provide exclusive management back-office operational and ASIC colocation services to American Bitcoin. As a result of the Transactions, American Bitcoin became a subsidiary of Hut 8 in which the Company held a 3.17% minority interest in American Bitcoin represented by 23,199,205 shares of common stock. The Company also entered into a lock-up agreement (“Lock-Up Agreement) restricting the Company’s sale of any shares owned, until a pre-determined amount of time after any merger or other go-public events of American Bitcoin.

     

    On June 27, 2025, American Bitcoin consummated a private placement pursuant to which it raised gross proceeds of approximately $220 million from the sale of American Bitcoin’s Class A common stock at a per share purchase price of $20 (the “Private Placement”) for which Dominari Securities acted as placement agent. The Class A and Class B common stock had the same rights, powers and privileges and were identical in all respects as to all matters. As a result of the Private Placement, the Company held an approximate 2.6% minority interest in American Bitcoin and adjusted the carrying value of its 1.6 million shares of American Bitcoin’s Class B common stock, which was exchangeable with the Class A common stock on a one for one basis, to $32.0 million at June 30, 2025. As of June 30, 2025, the carrying value of the American Bitcoin investment was recorded within the long-term equity investments caption of the Company’s unaudited condensed consolidated balance sheet.

     

    On September 2, 2025, Gryphon Digital Mining, Inc. (NASDAQ:GRYP), a bitcoin mining company that offers carbon-neutral bitcoin mining and digital mining operations, entered into a definitive merger agreement with American Bitcoin Corp. to form a combined company that would operate under the brand American Bitcoin and be led by the board of directors of American Bitcoin and would be listed for trading on NASDAQ under the ticker symbol “ABTC”. As part of the Merger, a 14.4995-for-1 stock split was completed, resulting in the Company receiving 23,199,205 shares of ABTC common stock. ABTC began trading on NASDAQ for $8.00 per share, on September 3, 2025.

     

    As of September 30, 2025, the Company valued its investment in ABTC using the quoted market price of $6.74 per share resulting in a fair value of approximately $156.4 million, recorded within the marketable securities caption of the condensed consolidated balance sheet. The Company recorded the entire associated unrealized gain of $156.4 million within the gain (loss) on marketable securities” caption of the unaudited condensed consolidated statement of operations for the three and nine months ended September 30, 2025. As a result of the Lock-Up Agreement, the Company is restricted from selling, transferring, or otherwise disposing of any ABTC shares until March 1, 2026.

     

    12

     

    Note 6. Notes Receivable

     

    The following table presents the Company’s notes receivable as of September 30, 2025 and December 31, 2024 ($ in thousands):

     

    September 30, 2025

       Maturity
    Date
      Stated
    Interest
    Rate
       Principal
    Amount
       Interest
    Receivable
       Fair
    Value
     
    Notes receivable, at fair value                   
    American Innovative Robotics  04/01/2027   8%  $
    -
       $
    -
       $
    -
     
                            
    Notes receivable, at fair value - current portion                    $
    -
     
                            
    Notes receivable, at fair value - non-current portion                    $
    -
     

     

    December 31, 2024

       Maturity
    Date
      Stated
    Interest
    Rate
       Principal
    Amount
       Interest
    Receivable
       Fair
    Value
     
    Notes receivable, at fair value                   
    Raefan Industries LLC  06/30/2025   8%  $
    -
       $
    -
       $
    -
     
    American Innovative Robotics  04/01/2027   8%  $1,106   $23   $902 
                            
    Notes receivable, at fair value - current portion                    $
    -
     
                            
    Notes receivable, at fair value - non-current portion                    $902 

     

    American Innovative Robotics, LLC

     

    The Company recorded interest income of approximately $20,000, and an unrealized gain on the note of approximately $221,000 on the American Innovative Robotics Promissory Note for the nine months ended September 30, 2025. The note was fully paid off as of March 24, 2025, resulting in an ending value of $0.

     

    Raefan Industries LLC

     

    During 2024, the Company deemed that the note for Raefan Industries LLC was uncollectible, and as a result, the Company recorded a realized loss as a result of directly writing off the note on Raefan Industries LLC, resulting in an ending value of $0 for the period ended September 30, 2025 and December 31, 2024. On June 30, 2025, the Company executed a Note Modification Agreement to extend the maturity date of the note to December 31, 2025. As of September 30, 2025, the Company maintained the note as uncollectible and fully written off.

     

    13

     

    Note 7. Fair Value of Financial Assets and Liabilities

     

    Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

     

    The Company uses three levels of inputs that may be used to measure fair value:

     

    Level 1 - quoted prices in active markets for identical assets or liabilities

     

    Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

     

    Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

     

    Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

     

    Warrants

     

    Included in the September 30, 2025 warrants in level 2 financial assets that were acquired in connection with fees related to the Company’s underwriting services is approximately $1.2 million of warrants for purchasing shares in publicly traded that are subject to lock-up periods that will end in November 2025 and another $4.0 million of warrants for purchasing shares in publicly traded companies with lock-up periods that will end by March 1, 2026. The fair value of these warrants was measured considering the lock-up periods and applying a discount for lack of marketability (DLOM). The DLOM calculation incorporated observable inputs including each company’s historical volatility, applicable treasury rates, and the remaining duration of the lock-up period.

     

    Notes Receivable at fair value

     

    As of September 30, 2025, the fair value of the notes receivable was measured taking into consideration cost basis, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. 

     

    The following table presents the Company’s assets and liabilities that are measured at fair value as of September 30, 2025, and December 31, 2024 ($ in thousands):

     

       Fair value measured as of September 30, 2025 
           Quoted   Significant     
       Total at
    September 30,
       prices in
    active
    markets
       other
    observable
    inputs
       Significant
    unobservable
    inputs
     
       2025   (Level 1)   (Level 2)   (Level 3) 
    Assets                
    Marketable securities:                
    Equities  $163,362   $163,362        $
    -
     
    Warrants   7,476    
    -
       $7,476      
    Total marketable securities  $170,838   $163,362   $7,476   $
    -
     

     

       Fair value measured as of December 31, 2024 
           Quoted   Significant     
           prices in   other   Significant 
       Total at
    December 31,
       active
    markets
       observable
    inputs
       unobservable
    inputs
     
       2024   (Level 1)   (Level 2)   (Level 3) 
    Assets                
    Marketable securities:                    
    Equities  $4,156   $4,156   $
    -
       $
    -
     
    Warrants   1,617         1,617      
    Total marketable securities  $5,773   $4,156   $1,617   $
    -
     
    Notes receivable at fair value, current portion  $
    -
       $
    -
       $
    -
       $
    -
     
    Notes receivable at fair value, non-current portion  $902   $
    -
       $
    -
       $902 

     

    14

     

    Level 3 Measurement

     

    The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

     

    Notes receivable at fair value, non-current portion at December 31, 2024  $902 
    Unrealized gain (loss) on notes receivable   221 
    Change in interest receivable   20 
    Collection of principal and interest outstanding   (1,143)
    Notes receivable at fair value, non-current portion at September 30, 2025  $
    --
     
          
    Notes receivable at fair value, current portion at December 31, 2023  $3,177 
    Collection of principal outstanding   750)
    Realized and unrealized gain and loss on note receivable, net   (2,086)
    Change in interest receivable   (56)
    Notes receivable at fair value, current portion at September 30, 2024  $285 
          
    Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 
    Unrealized loss on notes receivable   (1)
    Notes receivable at fair value, non-current portion at September 30, 2024  $1,128 

     

    Note 8. Leases

     

    On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date”). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

     

    On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financials’ Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financials’ Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financials’ Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financials’ Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financials’ Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

     

    On September 2, 2025, the Company entered into a Lease Agreement (the “Company’s Florida Lease”) with Blue Diamond Towers, LLC, a Delaware limited liability company. Under the Company’s Florida Lease, the Company rents a portion of the first floor designated as Suite 103 of the North Building at 3835 PGA Boulevard in Palm Beach Gardens, Florida, (the “Florida Premises”). The Company will use the Florida Premises as Executive Offices. The initial term of the Company’s Florida Lease is two (2) years commencing on October 1, 2025. Under the Company’s Florida Lease, the Company is required to pay monthly rent, commencing on October 1, 2025, equal to $10,000. Effective for the second year of the Company’s Florida Lease, the rent shall increase to $10,300. The Company took possession of Florida Premises in October 2025.

     

    The tables below represent the Company’s lease assets and liabilities as of September 30, 2025: 

     

       September 30,
    2025
     
    Assets:    
    Operating lease right-of-use-assets  $2,862 
    Liabilities:     
    Current     
    Operating   530 
    Long-term     
    Operating   2,464 
       $2,994 

     

    15

     

    The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

     

       September 30,
    2025
     
    Weighted-average remaining lease term - operating leases (in years)   4.5 
    Weighted-average discount rate - operating leases   10.0%

     

    During the three and nine months ended September 30, 2025, and 2024, the Company recorded approximately $0.2 million and $0.4 million, respectively, of lease expense to current period operations.

     

       Three Months   Nine Months 
       Ended   Ended 
       September 30,   September 30, 
       2025   2025 
    Operating leases        
    Operating lease cost  $178   $535 
    Short-term lease rent expense   2    8 
    Net rent expense  $180   $543 

     

       Three Months   Nine Months 
       Ended   Ended 
       September 30,   September 30, 
       2024   2024 
    Operating leases        
    Operating lease cost  $178   $534 
    Short-term lease rent expense   23    96 
    Net rent expense  $201   $630 

     

    Supplemental cash flow information related to leases were as follows:

     

       Nine Months 
       Ended 
       September 30, 
       2025 
    Operating cash flows - operating leases  $511 

     

    As of September 30, 2025, future minimum payments during the next five years and thereafter are as follows:

     

       Operating 
       Leases 
    Remaining Period Ended December 31, 2025  $217 
    Year Ended December 31, 2026   805 
    Year Ended December 31, 2027   801 
    Year Ended December 31, 2028   766 
    Year Ended December 31, 2029   784 
    Thereafter   377 
    Total  $3,750 
    Less present value discount   (756)
    Operating lease liabilities  $2,994 

     

    16

     

    Note 9. Net Income (Loss) per Share

     

    Basic income (loss) per share of common stock is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed similar to basic income (loss) per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period.

     

    The calculation of the Company’s diluted number of shares for the three and nine months ended September 30, 2025 is as follows:

     

       For the
    three  months
    ended September 30,
    2025
      

    For the
    nine months
    ended September 30,
    2025 

     
    Weighted average shares - basic   15,442,342    13,700,375 
               
    Effect of dilutive potential common shares:          
    Convertible preferred stock   34    34 
    Warrants to purchase common stock   1,732,975    154,913 
               
    Restricted stock awards   49,706    47,628 
               
               
               

    Weighted average shares – diluted 

       17,223,257    13,902,950 

     

    Warrants to purchase 357,198 shares of common stock were outstanding during the three- and nine-months period ended September 30, 2025 that were not included in the computation of diluted EPS because the exercise price was greater than the average market price of the common shares. As of September 30, 2025,  253,670 warrants expire in February 2026 and 103,528 warrants expire in February 2027. All such warrants were still outstanding at the end of September 30, 2025.

     

    Options to purchase  10,036,333 shares of common stock that were outstanding during the three and nine months period ended September 30, 2025 were not included in the computation of diluted EPS because either the exercise price was greater than the average market price of the common shares or those where the exercise price was below the average market price of the common shares were antidilutive. These options, which expire between August 2026 in February 2035, were still outstanding at the end of September 30, 2025.

     

    Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the nine months ended September 30, 2024 included 34 shares of convertible preferred stock, 444,796 warrants to purchase common stock, 40,000 shares of restricted stock awards, and 419,988 stock options totaling to 904,818 shares.

     

    Note 10. Stockholders’ Equity and Convertible Preferred Stock

     

    Common Stock

     

    As of September 30, 2025, 15,817,323 shares of common stock were issued and outstanding.

     

    On February 10, 2025, the Company entered into securities purchase agreements with certain accredited investors for the sale by the Company of 1,439,467 registered shares of its common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants in a direct offering. In a concurrent private placement, the Company entered into securities purchase agreements with certain accredited investors for the sale of 2,436,587 unregistered shares of common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants (the “February 2025 Financings”). The Series A warrants are exercisable immediately upon issuance at an exercise price of $3.72 per share and will expire five years from the date of issuance. The Series B warrants are exercisable immediately upon issuance at an exercise price of $4.22 per share and will expire five years from the date of issuance. The net proceeds to the Company from the February 2025 Financings were approximately $13.5 million.

     

    On February 10, 2025, the Company entered into advisory agreements with various individuals who were issued shares of common stock. The agreements are for a term of two years but are cancellable by either party. As part of these agreements, 2,550,000 shares of common stock were issued on February 18, 2025. An additional 850,000 shares may be issued under the terms of the agreements when certain provisions are met, which as of the date of grant is probable. These shares are nonforfeitable and thus were fully expensed by the Company at the time of grant. The Company used a Monte Carlo simulation to calculate the grant date fair value of the common stock. The fair value of issued shares amounted to $20.9 million and is presented in general and administrative expenses on the unaudited condensed consolidated statement of operations.

     

    17

     

    The securities in the concurrent private placement were offered under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered shares, the warrants, and the shares of common stock underlying the warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

     

    Certain officers, directors, employees and members of the Company’s advisory board participated in the February 2025 Financings on the same terms as the other investors.

     

    During the period April 1, 2025 to September 30, 2025 warrants were exercised by various individuals resulting in additional common stock issuance of 1,173,429 shares generating cash proceeds of $4.6 million which is included in additional paid-in capital on the unaudited condensed consolidated statements of changes in stockholders’ equity.

     

    Series D Convertible Preferred Stock

     

    In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.

     

    As of September 30, 2025 and December 31, 2024, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.

     

    Series D-1 Convertible Preferred Stock

     

    The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.

     

    As of September 30, 2025 and December 31, 2024, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.

     

    Dividends

     

    On February 11, 2025, the board of directors approved a special cash dividend of $0.32 per share payable on March 3, 2025, to holders of common stock and certain warrant holders as of close of business on February 24, 2025. On September 9, 2025, the board of directors approved a special cash dividend of $0.22 per share payable on September 26, 2025, to holders of common stock and certain warrant holders as of close of business on September 3, 2025. Cash dividends paid in 2025 totaled $12.0 million and have been charged to accumulated deficit. Dividends paid for the three months ended March 31, 2025, totaled $7.1 million, and dividends paid for the three months ended September 30, 2025 totaled $4.9 million.

     

    18

     

    Treasury Stock

     

    There were 60,148 shares of treasury stock on December 31, 2024. The Company retired such shares in July 2025 and there were no shares of treasury stock as of September 30, 2025.

     

    Warrants

     

    A summary of warrant activity for the nine months ended September 30, 2025, is presented below:

      

           Weighted       Weighted
    Average
    Remaining
     
           Average
    Exercise
       Total
    Intrinsic
       Contractual
    Life
     
       Warrants   Price   Value   (in years) 
    Outstanding as of December 31, 2024   444,796   $29.25    
    -
        1.20 
    Granted   7,752,108    3.97    
     
          
    Expired   (87,598)  $28.74    
    -
        - 
    Exercised   (1,173,426)   3.96    
     
          
    Outstanding as of September 30, 2025   6,935,880   $5.33    
    -
        4.1 

     

    Restricted Stock Awards and Stock Options

     

    On October 7, 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”). The 2022 Plan provided for the issuance of up to 1,100,000 shares in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The 2022 Plan expires on January 1, 2032, and is administered by Dominari Holdings Board of Directors.

     

    On February 10, 2025, the Company issued 50,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $308,000.

     

    On February 10, 2025 the Company issued 351,851 shares of the Company’s common stock to Messrs. Christopher Devall under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $2.1 million.

     

    On February 12, 2025 in connection with the closing of the PIPE, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant to Messrs. Anthony Hayes. Pursuant to the Committee’s decision, he received 500,000 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $3.4 million.

     

    On March 11, 2025, the Company executed grant agreements with each of Messrs. Anthony Hayes and Kyle Wool pursuant to their employment agreements with the Company, and in accordance with the Company’s 2022 Equity Incentive Plan. Pursuant to the grant agreements, each received 154,559 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $1.7 million.

     

    See Restricted Stock roll-forward below.

     

    A summary of restricted stock awards activity for the nine months ended September 30, 2025, is presented below: 

     

       Number of   Weighted 
       Restricted
    Stock
    Awards
       Average
    Grant Day
    Fair Value
     
    Nonvested at December 31, 2024   50,000   $0.98 
    Granted   1,210,969   $6.30 
    Vested   (1,210,969)  $6.30 
    Forfeited   
    -
       $
    -
     
    Nonvested at September 30, 2025   50,000   $0.98 

     

    19

     

    Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $7.7 million and $0.8 million for the nine months ended September 30, 2025, and 2024, respectively. Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $12,000 and approximately $41,000 for the three months ended September 30, 2025, and 2024, respectively All stock compensation was recorded as a component of general and administrative expenses.

     

    As of September 30, 2025, there is approximately $12,000 unrecognized stock-based compensation expense related to restricted stock awards.

     

    Stock Options

     

    On February 10, 2025, the Company granted an additional 5.0 million fully vested nonqualified stock options (each, a “Performance Award” and collectively, the “Performance Awards”) each to Anthony Hayes and Kyle Wool conditioned upon either the Company’s shareholders approving the Performance Awards or approving an increase in the share reserve of the Company’s 2022 Equity Incentive Plan (the “Plan”) such that the full number of shares underlying the Performance Awards could be delivered under the Plan. On April 1, 2025, following a special meeting of shareholders, the Company’s shareholders voted to approve an increase in the Plan’s share reserve allowing the Performance Awards to be delivered under the Plan. As of September 30, 2025, the Company recorded an expense of $26.1 million for the Performance Awards.

     

    A summary of option activity under the Company’s stock option plan for the nine months ended September 30, 2025, is presented below:

     

                   Weighted 
                   Average 
           Weighted   Total   Remaining 
          Average   Intrinsic   Contractual 
       Number of
    Shares
       Exercise
    Price
       Value
    ($000s)
       Life
    (in years)
     
    Outstanding as of December 31, 2024   376,654   $4.29   $
    -
        8.2 
    Employee options granted   10,000,000   $3.85         9.8 
    Employee options exercised   (30,000)   3.36           
    Employee options expired   (128,652)  $3.68           
    Employee options forfeited   (181,669)  $3.50   $4    - 
    Outstanding as of September 30, 2025   10,036,333   $6.18   $9,336    9.4 
    Options vested and exercisable   10,021,333   $6.18   $9,330    9.4 

     

    Stock-based compensation associated with the amortization of stock option expense was $0.0 million and $0.1 million for the three months ended September 30, 2025, and 2024, respectively. Stock based compensation associated with the amortization of stock option expense was approximately $26.2 million and $0.3 million for the nine months ended September 30, 2025, and 2024 respectively. All stock compensation was recorded as a component of general and administrative expenses. 

     

    The following were assumptions used in the Company’s fair value analysis:

     

    Risk-free interest rate   4.14%
    Estimated maturity date   10 years 
    Underlying stock price   6.16 
    Expected volatility   112.5%

     

    Estimated future stock-based compensation expense relating to unvested stock options is approximately $52,000 

     

    Non-controlling Interest

     

    As previously discussed, the Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the unaudited condensed consolidated statements of changes in stockholders’ equity. As of September 30, 2025, the amount attributable to non-controlling interest was $1.9 million out of which $0.1 million is still outstanding payable to non-controlling interests.

     

    20

     

    Note 11. Revenue

     

    The following table presents our total revenue disaggregated by revenue type for the three and nine months ended September 30, 2025 and 2024 (in thousands):

     

       Three Months Ended   Nine Months Ended 
       September 30,   September 30, 
       2025   2024   2025   2024 
    Underwriting  $32,745   $1,971   $57,828   $6,360 
    Commissions   8,881    1,161    14,570    3,246 
    Account advisory and management fees   269    638    555    1,409 
    Carried interest fees   8,704    
    -
        19,204    
    -
     
    Other   222    273    869    569 
    Total  $50,821   $4,043   $93,026   $11,584 

     

    Note 12. Commitments and Contingencies

     

    Legal Proceedings

     

    The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Company’s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Company’s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be.

     

    In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

     

    In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

     

    Note 13. Regulatory

     

    Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of September 30, 2025, Dominari Securities had net capital of approximately $15.8 million in excess of net capital requirement of $0.7 million.

     

    21

     

    Note 14. Related Party Transactions

     

    In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to assist in the management and building of the Company’s investment processes. Kyle Wool, one of the Company’s board members, was previously a member of the board of directors of Revere until June 2023 and held approximately 30% of Revere’s outstanding equity until May 20, 2025. From time to time, Company participates in offerings of securities as an underwriter in transactions in which Revere is also participating as an underwriter. On such transactions, the Company earned $0 and $103,470 in the three months ending September 30, 2025, and 2024, respectively. On such transactions, the Company earned $318,405 and $313,960 in the nine months ending September 30, 2025, and 2024, respectively. As of May 20, 2025, Kyle Wool no longer holds an equity interest in Revere.

     

    The Company collected fees on behalf of Series which were intended for future expenses of each Series entity. As of September 30, 2025, such amount was approximately $53,000 and is included in other current liabilities on the accompanying unaudited condensed consolidated balance sheet.

     

    During the year ended December 31, 2024, the Company entered into employee loans with various employees totaling $2.4 million. The terms of the loan agreements range from 3 years to 7 years, with an average annual interest rate of approximately 3.2%. The total interest received for the three months ended September 30, 2024 and 2025 was approximately $11,000 and $20,000 respectively and for the nine month ended September 30, 2024 and 2025 was approximately $32,000 and $58,000 respectively. As of September 30, 2025 and December 31, 2024, the total outstanding balance of the employee loans was $1.9 million and $2.2 million respectively included in loans to employees on the accompanying unaudited condensed consolidated balance sheets.

     

    Certain of the Company’s investments are made through related party special purpose vehicles. These are included within Note 5 of the unaudited condensed consolidated financial statements and include the following investments: investment in Revere Master SPV Series 1 (Qxpress Pte Ltd), investment in Revere Master SPV Series VI (TessPay, Inc.), investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI), investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.), investment in Dominari Master SPV LLC Series XII (Groq, Inc.). These investments are classified in long term equity investments on the balance sheet.

     

    The Company’s investments in American Ventures LLC Series XIX (Skyline Builders Group Holdings Ltd.), and American Ventures LLC Series XIV (JFB Construction Holdings) are classified as marketable securities.

     

    The Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the unaudited condensed consolidated statements of changes in stockholders’ equity. As of September 30, 2025, the amount attributable to non-controlling interest was $1.9 million out of which $0.1 million is still outstanding payable to non-controlling interests.

     

    The Company earns revenues for managing certain pooled investment vehicles which are related parties. These include the entirety of the carried interest fees revenues, and management fee revenues included within the advisory and management fees caption, of the unaudited condensed consolidated statements of operations. As of September 30, 2025, the total amount of contract liabilities disclosed in Note 2 represented amounts received in advance of revenue earned on managing such related party investment vehicles.

     

    Note 15. Segment Reporting

     

    Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

     

    The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Dominari Labs (formerly Aikido Labs), which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.

     

    The CODM has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.”

     

    22

     

    The measures of segment profitability that are most relied upon by the CODM are gross revenue and net income (loss), as presented within the table below and reconciled to the unaudited condensed consolidated statements of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis. 

     

       Three Months Ended September 30, 2025
       Dominari Financial   Legacy AIkido Pharma   Consolidated 
    Revenue  $50,150   $671   $50,821 
    Operating Costs               
    Compensation and benefits   41,025    9,260    50,285 
    Professional and consulting fees   255    1,185    1,440 
    Data processing   187    
    -
        187 
    Other expenses   (58)   566    508 
    Income (loss) from operations   8,741    (10,340)   (1,599)
                    
    Other (expenses) income               
    Interest income   497    53    550 
    Gain on marketable securities   1,213    157,917    159,130 
    Unrealized loss on note receivable   
    -
        
    -
        
    -
     
    Change in fair value of investments   
    -
        (32,000)   (32,000)
    Total other (expenses) income   1,710    125,970    127,680 
    Net income  $10,451   $115,630   $126,081 
    Less: Net income attributable to non-controlling interests   871    
    -
        871 
    Net income attributable to common stockholders of Dominari Holdings  $9,580   $115,630   $125,210 
    Total assets  $83,124   $140,322   $223,446 

     

    23

     

       Three Months Ended September 30, 2024
       Dominari Financial   Legacy AIkido Pharma   Consolidated 
    Revenue  $3,684   $359   $4,043 
    Operating Costs               
    Compensation and benefits   3,798    1,613    5,411 
    Professional and consulting fees   232    267    499 
    Data processing   241    32    273 
    Other expenses   167    889    1,056 
    Loss from operations   (754)   (2,442)   (3,196)
                    
    Other (expenses) income               
    Interest income   204    76    280 
    Gain on marketable securities   
    -
        89    89 
    Unrealized loss on note receivable   
    -
        (429)   (429)
    Change in fair value of investments   
    -
        (955)   (955)
    Total other (expenses) income   204    (1,219)   (1,015)
    Net loss  $(550)  $(3,661)  $(4,211)
    Total assets  $16,062   $27,369   $43,431 

     

       Nine Months Ended September 30, 2025 
       Dominari
    Financial
       Legacy
    AIkido
    Pharma
       Consolidated 
    Revenue  $92,355   $671   $93,026 
    Operating Costs               
    Compensation and benefits   78,455    59,996    138,451 
    Professional and consulting fees   1,613    2,453    4,066 
    Data processing   546    
    -
        546 
    Other expenses   675    2,323    2,998 
    Income (loss) from operations   11,066    (64,101)   (53,035)
                    
    Other (expenses) income               
    Interest income   878    95    973 
    Gain on marketable securities   4,539    158,555    163,094 
    Unrealized gain on note receivable   
    -
        221    221 
    Change in fair value of investments   
    -
        
    -
        
    -
     
    Total other income   5,417    158,871    164,288 
    Net income (loss)  $16,483   $94,770   $111,253 
    Less: Net income attributable to noncontrolling interests   1,921    
    -
        1,921 
    Net income attributable to common stockholders of Dominari Holdings  $14,562   $94,770   $109,332 
    Total assets  $83,124   $140,322   $223,446 

     

    24

     

       Nine Months Ended September 30, 2024 
       Dominari
    Financial
       Legacy
    AIkido
    Pharma
       Consolidated 
    Revenue  $10,553   $1,031   $11,584 
    Operating Costs               
    Compensation and benefits   10,037    4,210    14,247 
    Professional and consulting fees   993    924    1,917 
    Data processing   616    77    693 
    Other expenses   1,697    1,767    3,464 
    Loss from operations   (2,790)   (5,947)   (8,737)
                    
    Other (expenses) income               
    Interest income   545    184    729 
    Gain on marketable securities   
    -
        767    767 
    Unrealized loss on note receivable   
    -
        (2,086)   (2,086)
    Change in fair value of investments   
    -
        (6,445)   (6,445)
    Total other (expenses) income   545    (7,580)   (7,035)
    Net loss  $(2,245)  $(13,527)  $(15,772)
    Total assets  $16,062   $27,369   $43,431 

     

    Note 16. Income Taxes 

     

    The Company recorded no income tax expense for the nine months ended September 30, 2025 and 2024 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

     

    As of September 30, 2025, and December 31, 2024, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

     

    The One Big Beautiful Bill Act (OBBBA) was enacted on July 4, 2025. The Company has evaluated whether OBBBA has a material impact on its 2025 unaudited condensed consolidated financial statements. The only provision of OBBBA that impacts the Company’s income tax accounting under ASC740 is the new IRC. Sec. 174A, which permanently allows taxpayers to fully expense domestic research or experimental (R&E) expenditures paid or incurred in taxable years beginning after December 31, 2024. The requirement to capitalize foreign Sec. 174 expenses over 15 years has not changed. On August 28, 2025, the IRS released procedural guidance (Rev. Proc. 2025-28) for implementing Section 174A and related elections for domestic research or experimental expenditures. Transition rules provide taxpayers with options to account for any remaining unamortized domestic R&E expenditures paid or incurred in taxable years beginning after December 31, 2021, and before January 1, 2025. Taxpayers may continue to amortize such unamortized amounts over the remaining five-year period; alternatively, they may elect to deduct any remaining unamortized domestic R&E expenditures either entirely in the first tax year beginning after December 31, 2024, or ratably over two taxable years (e.g., 2025 or ratably in 2025 and 2026). The Company plans to elect to deduct the remaining unamortized costs entirely in 2025. As of December 31, 2024, the Company has approximately $415,000 of remaining unamortized domestic R&D expenditures eligible for immediate deduction, representing approximately $119,000 of its December 31, 2024 gross Deferred Tax Assets. The impact of deducting these costs is reclassifying approximately $119,000 from Capitalized Sec. 174 to Net Operating Loss Carryforward, with zero net impact on the Company’s gross deferred tax assets or effective tax rate.

     

    25

     

    Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     

    You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-Q. All references to “we,” “us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation and its consolidated subsidiaries unless the context requires otherwise.

     

    Cautionary Note Regarding Forward-Looking Statements

     

    This Quarterly Report on Form 10-Q (“Quarterly Report”) contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance, business strategies or expectations for the Company’s business. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Quarterly Report, words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company’s actual results or performance may be materially different from those expressed or implied by these forward-looking statements.

     

    Overview

     

    Dominari Holdings Inc. (“Dominari”) is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. Dominari and its subsidiaries are collectively referred to herein as “Company,” “we,” “our” or “us.”

     

    Dominari Financial Inc. (“Dominari Financial”), a wholly owned subsidiary of Dominari Holdings Inc., executes the Company’s growth strategy in the financial services industry. In addition to organic growth, Dominari Financial seeks partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and insurance brokers. Our first transaction in furtherance of our growth in the financial services industry, the acquisition of 100% of a dually registered broker dealer and investment advisor from Fieldpoint Private Bank & Trust (“Fieldpoint”), was consummated on March 27, 2023. The newly acquired dually registered broker-dealer and investment adviser was renamed Dominari Securities LLC (“Dominari Securities”) and is a wholly owned subsidiary of Dominari Financial.

     

    On October 13, 2023, the Company entered into two separate Limited Liability Company Agreements with Dominari Manager LLC (“Manager”) and Dominari IMLLC (“Investment Manager”) which are both wholly owned subsidiaries and whose operations are included within the unaudited condensed consolidated financial statements of Dominari. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

     

    On May 21, 2024, Dominari Financial and Heritage Strategies LLC (“HS”) entered into a Limited Liability Company Operating Agreement (the “JV Agreement”) of Dominari Financial Heritage Strategies LLC (“DFHS”). The JV Agreement governs the operation of DFHS, including the distributions to the members of DFHS upon the offer, sale and renewal of various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. Pursuant to the terms of the JV Agreement, Dominari Financial and HS are the co-managing members (the “Co-Managing Members”), each with fifty percent (50%) ownership interests in DFHS. Revenues from the sale of the various insurance products and services after deducting general and administrative costs are distributed to the Co-Managing Members as set forth in the JV Agreement.

     

    26

     

    On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”) and was assigned ninety percent (90%) Membership Interest in each, which are both ninety percent (90%) majority owned subsidiaries of the Company and whose operations are included within the unaudited condensed consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

     

    Critical Accounting Estimates

     

    We prepare our unaudited condensed consolidated financial statements in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Our actual results could differ significantly from these estimates under different assumptions and conditions.

     

    In addition to our critical accounting estimates as compared to the critical accounting estimates discussed in the Company’s Annual Report on Form 10- K, the Company considers the valuation of its warrants as a critical accounting estimate included in the September 30, 2025 unaudited condensed consolidated financial statements as follows:

     

    Warrant Investments

     

    Warrant fair values are primarily determined using a Black Scholes option pricing model, which include the underlying stock price, warrant strike price, expected remaining term, volatility, and risk-free rate as the primary inputs to the model. Increases or decreases in any of these inputs could result in a material change in fair value. Additionally, for warrants that have periods of contractual trading restrictions, marketability discounts were considered in determining fair value.

     

    ●The underlying stock price is equal to the closing price of the underlying stock as of the measurement date.
       
    ●The expected remaining term is equal to the time to expiration of the warrant investment.
       
    ●Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant investment price.
       
    ●The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining term of the warrant investment.
       
    ●Marketability discounts are applied for warrants that have sales restrictions (or lock up periods). These discounts are calculated using a combination of the Finnerty Model and the Asian Put Model using a term equal to the period of such restriction.

     

    Refer to Note 3 of the Company’s Annual Report on Form 10-K for a discussion of our significant accounting policies.

     

    27

     

    Recently Issued Accounting Pronouncements

     

    See Note 3 to the unaudited condensed consolidated financial statements for a discussion of recent accounting standards.

     

    Results of Operations

     

    Three months ended September 30, 2025, compared to the three months ended September 30, 2024

     

    During the three months ended September 30, 2025 and 2024, we recognized approximately $50.8 million and $4.0 million in revenue from operations, respectively. The increase in 2025 was primarily driven by the increase in commissions of $7.7 million and underwriting revenue of $30.8 million earned by Dominari Securities and Dominari Manager LLC (“Manager”) along with $8.7 million earned in carried interest for the three months ended September 30, 2025. During the three months ended September 30, 2025, we recorded net income of approximately $126.1 million and during the three months ended September 30, 2024, we incurred a net loss of approximately $4.2 million. The change in net income from operations was primarily driven by increases in revenue and other income (see discussion below on marketable securities and long-term equity investments), and was offset by increases in general and administrative costs and expenses, specifically increases in commissions expense and stock-based compensation expense.

     

    During the three months ended September 30, 2025, other income was approximately $127.7 million and the Company recorded an other expense of $1.0 million, for the comparable period in 2024.

     

    The activity described above for the three months ended September 30, 2025 and 2024, is primarily a result of the Company’s continued increase in activities related to the financial services industry, overall volatility in investment valuations due to macroeconomic uncertainty impacting marketable securities and the change in carrying value of long-term equity investments. Specifically:

     

      i. Marketable securities - We recognized net gains of approximately $159.1 on marketable securities during the quarter primarily driven by an unrealized gain of $156.4 million from the investment in American Bitcoin Corp. (“ABTC”) along with gains recorded on investments in Skyline Builders Group Holdings Ltd. and JFB Construction Holdings.  In September 2025, ABTC became publicly listed on the Nasdaq (Ticker: ABTC) and accordingly, the ABTC investment was reclassified from long term equity investments to marketable securities.
         
      ii. Long-term equity investments – During the three months ended September 30, 2025, we recognized a reduction of $32.0 million in our long-term equity investments reflecting the reclassification of the American Bitcoin Corp investment to marketable securities which was valued at $32.0 million at June 30, 2025.  

     

    Nine months ended September 30, 2025, compared to the nine months ended September 30, 2024

     

    During the nine months ended September 30, 2025, and 2024, we recognized approximately $93.0 million and $ 11.6 million in revenue from operations, respectively. The increase was primarily driven by the increase in commission revenues of $11.3 million and underwriting revenue of $51.5 million earned by Dominari Securities and Dominari Manager LLC (“Manager”) along with $19.2 million earned in carried interest for the nine months ended September 30, 2025. During the nine months ended September 30, 2025, and 2024, we recorded net income of $111.2 million and a net loss of approximately $15.8 million respectively. The change in net income was primarily driven by increases in revenues of $81.4 million and other income of $164.8 million offset by an increase in stock-based compensation expense of $53.7 million, and commission expenses of $60.4 million as compared to the comparable period in 2024. During the nine months ended September 30, 2025 and 2024, other income (expenses) were approximately $164.8 million and ($7.0 million), respectively (see discussion below on marketable securities and long-term equity investments).

     

    28

     

    The activity described above for the nine months ended September 30, 2025 and 2024, is primarily a result of the Company’s continued increase in activities related to the financial services industry, along with macroeconomic uncertainty and volatility impacting marketable securities. Specifically:

     

      i. Marketable securities - We recognized gains of approximately $163.1 million on marketable securities, which includes $156.4 million gain from the Company’s investment in ABTC (see discussion above) for the nine months ended September 30, 2025. This represents an increase of approximately $162.3 million over the nine months ended September 30, 2024.
         
      ii. Notes receivable - We recognized $0.2 million unrealized gain over the nine months ended September 30, 2025, versus $2.0 million loss during the nine months ended September 30, 2024, on notes receivable.

     

    Liquidity and Capital Resources

     

    We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

     

    ●managing current cash and cash equivalents on hand from our past debt and equity offerings;

     

    ●managing current marketable securities and other investments on hand ;

     

    ●seeking additional funds raised through the sale of additional securities in the future; and

     

    ●seeking additional liquidity through credit facilities or other debt arrangements.

     

    Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our longer-term business plan to support our transition into the financial services industry. Our working capital amounted to approximately $198.8 million as of September 30, 2025. Included in working capital is $156.4 million related to American Bitcoin shares that is subject to a lock-up period until March 1, 2026. as well as another $1.2 million of warrants for purchasing shares in publicly traded that are subject to lock-up periods that will end in November 2025 and an additional $4.0 million of warrants for purchasing shares in publicly traded companies with lock-up periods that will end by March 1, 2026. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly traded company or from continuing operations.

     

    29

     

    Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders.

     

    The following table summarizes our net cash flows from operating, investing and financing activities for the periods indicated (in thousands):

     

       As of September 30, 
       2025   2024 
    Cash provided by (used in)        
    Operating activities  $(4,031)  $(11,902)
    Investing activities   945    12,472 
    Financing activities   4,380    - 
    Net increase in cash  $1,294   $570 

     

    Cash Flows from Operating Activities

     

    For the nine months ended September 30, 2025 we used $4.0 million in operations as compared to cash flow use of $11.9 million for the nine months ended September 30, 2024. The cash provided by operating activities for the nine months ended September 30, 2025, is primarily attributable to increases in receivable from clearing brokers of $11.6 million, increase in accrued commissions of $2.7 million , increase in stock based comp of $53.7 million, changes in operating assets and liabilities of approximately $6.2 million, net realized and unrealized gain on marketable securities of approximately $4.8 million, offset by a change in prepaid expenses and other assets of approximately $0.2 million, and net income of approximately $111.2 million. The cash used in operating activities for the nine months ended September 30, 2024, is primarily attributable to a net loss of approximately $15.7 million, approximately $3.4 million of unrealized gain on marketable securities, increase in clearing broker deposits of $6.5 million, partially offset by approximately $3.8 million of realized gain on marketable securities, the change in carrying value of long term investments of approximately $6.4 million, and changes in operating assets and liabilities of $5.7 million.

     

    Cash Flows from Investing Activities

     

    For the nine months ended September 30, 2025 and 2024, net cash provided by investing activities was approximately $0.9 million and $12.5 million, respectively. The cash provided by investing activities for the nine months ended September 30, 2025, sales of marketable securities of $15.9 million, collection of principal on notes receivable of $1.1 million, sales of long term investments $0.5 million and collection of principal from employee loans of $0.3 million, and was partially offset by purchases of marketable securities of approximately $16.8 million. The cash provided by investing activities for the nine months ended September 30, 2024, primarily resulted from our sale of marketable securities of approximately $14.8 million and long term investments of approximately $ 3.5 million and collections of principal on notes receivable of $0.8 million, and was partially offset by funds loaned to employees of $2.4 million and purchases of marketable securities of approximately $4.0 million.

     

    Cash Flows from Financing Activities

     

    For the nine months ended September 30, 2025, cash provided by financing activities was approximately $4.4 million, primarily driven by fund raising related to issuance of common stock of $13.5 million and issuance of common stock for warrants exercised of $4.6 million, partially offset by payment of dividends of $11.9 million. During the three months ended September 30, 2025, the Company distributed approximately $1.8 million to holders of non-controlling interests. For the nine months ended September 30, 2024, there are no cash flows from financing activities.  

     

    30

     

    Item 3. Quantitative and Qualitative Disclosures About Market Risk.

     

    Not Applicable.

     

    Item 4. Controls and Procedures

     

    Evaluation of Disclosure Controls and Procedures

     

    We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

     

    We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, as of September 30, 2025, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective due to the material weakness in our internal controls.

     

    A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

     

    Material Weaknesses in Internal Controls

     

    As of December 31, 2024, due to staffing and resource constraints, the Company required significant additional time to close the books and records. Management, after year end, continued to perform its account reconciliations which required further adjustments to be recorded. As such, information technology, business processes and financial reporting controls were deemed to be ineffective due to (a) the lack of personnel to ensure the books and records are closed accurately and on a timely basis, (b) lack of proper review over the accounting for certain notes receivable accounted for at fair value, (c) the lack of appropriate segregation of duties, (d) certain general information technology control deficiencies regarding user access provisioning and administrative access review, and (e) insufficient documentation to support and evidence the design and implementation of controls.

     

    Changes in Internal Control Over Financial Reporting

     

    On October 1, 2025, the Company hired an Interim Chief Financial Officer to assist the Company’s finance department. Otherwise, there were no changes in our internal control over financial reporting for the quarter ended September 30, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

     

    Limitations on Effectiveness of Controls

     

    Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

     

    31

     

    Part II - Other Information

     

    Item 1. Legal Proceedings

     

    The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Company’s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Company’s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be.

     

    In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

     

    In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

     

    Item 1A. Risk Factors

     

    As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. Our current risk factors are set forth in our Annual Report on Form 10-K, which was filed with the SEC on April 15, 2025. Any of our previously disclosed risk factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

     

    Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

     

    None.

     

    Item 3. Defaults Upon Senior Securities.

     

    None.

     

    Item 4. Mine Safety Disclosures.

     

    Not Applicable.

     

    Item 5. Other Information.

     

    None.

     

    32

     

    Item 6. Exhibits

     

    31.1*   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    31.2*   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    32.1**   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
    32.2**   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
    101.INS   Inline XBRL Instance Document
    101.SCH   Inline XBRL Taxonomy Extension Schema Document.
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

     

    *Filed herewith.

     

    **Furnished herewith.

     

    33

     

    Signatures

     

    Pursuant to the requirements of the Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      DOMINARI HOLDINGS INC.
         
    Date: November 10, 2025 By: /s/ Anthony Hayes
        Anthony Hayes  
        Chief Executive Officer

     

    Date: November 10, 2025 By: /s/ Tim Ledwick
        Tim Ledwick
        Chief Financial Officer

    34

    http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0000012239 false Q3 --12-31 0000012239 2025-01-01 2025-09-30 0000012239 2025-11-06 0000012239 2025-09-30 0000012239 2024-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2025-09-30 0000012239 us-gaap:SeriesDPreferredStockMember 2024-12-31 0000012239 domh:SeriesD1PreferredStockMember 2025-09-30 0000012239 domh:SeriesD1PreferredStockMember 2024-12-31 0000012239 2025-07-01 2025-09-30 0000012239 2024-07-01 2024-09-30 0000012239 2024-01-01 2024-09-30 0000012239 us-gaap:PreferredStockMember 2025-06-30 0000012239 us-gaap:CommonStockMember 2025-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-06-30 0000012239 us-gaap:RetainedEarningsMember 2025-06-30 0000012239 us-gaap:ParentMember 2025-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-06-30 0000012239 2025-06-30 0000012239 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0000012239 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000012239 us-gaap:ParentMember 2025-07-01 2025-09-30 0000012239 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0000012239 us-gaap:PreferredStockMember 2025-09-30 0000012239 us-gaap:CommonStockMember 2025-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-09-30 0000012239 us-gaap:RetainedEarningsMember 2025-09-30 0000012239 us-gaap:ParentMember 2025-09-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-09-30 0000012239 us-gaap:PreferredStockMember 2024-06-30 0000012239 us-gaap:CommonStockMember 2024-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-06-30 0000012239 us-gaap:RetainedEarningsMember 2024-06-30 0000012239 us-gaap:ParentMember 2024-06-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-06-30 0000012239 2024-06-30 0000012239 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000012239 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0000012239 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000012239 us-gaap:ParentMember 2024-07-01 2024-09-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0000012239 us-gaap:PreferredStockMember 2024-09-30 0000012239 us-gaap:CommonStockMember 2024-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-09-30 0000012239 us-gaap:RetainedEarningsMember 2024-09-30 0000012239 us-gaap:ParentMember 2024-09-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-09-30 0000012239 2024-09-30 0000012239 us-gaap:PreferredStockMember 2024-12-31 0000012239 us-gaap:CommonStockMember 2024-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-12-31 0000012239 us-gaap:RetainedEarningsMember 2024-12-31 0000012239 us-gaap:ParentMember 2024-12-31 0000012239 us-gaap:NoncontrollingInterestMember 2024-12-31 0000012239 us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0000012239 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0000012239 us-gaap:ParentMember 2025-01-01 2025-09-30 0000012239 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-09-30 0000012239 us-gaap:PreferredStockMember 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012239 us-gaap:RetainedEarningsMember 2023-12-31 0000012239 us-gaap:ParentMember 2023-12-31 0000012239 us-gaap:NoncontrollingInterestMember 2023-12-31 0000012239 2023-12-31 0000012239 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000012239 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0000012239 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000012239 us-gaap:ParentMember 2024-01-01 2024-09-30 0000012239 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 2022-10-04 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2025-09-30 0000012239 domh:DominariFinancialHeritageStrategiesLLCMember 2024-05-21 0000012239 domh:AmericanVenturesLLCMember 2025-06-17 0000012239 srt:ScenarioForecastMember domh:AmericanBitcoinSharesMember 2026-03-01 0000012239 2025-11-30 0000012239 srt:ScenarioForecastMember 2026-03-01 0000012239 domh:AmericanVenturesIMLLCAndAmericanVenturesManagerLLCMember 2025-09-30 0000012239 domh:DominariSecuritiesMember 2025-09-30 0000012239 2024-01-01 2024-12-31 0000012239 domh:InvestmentInAmericanBitcoinCorpMember 2025-07-01 2025-09-30 0000012239 domh:InvestmentInAmericanBitcoinCorpMember 2025-01-01 2025-09-30 0000012239 domh:InvestmentInAeonPartnersFundSeriesDBDatabricksIncMember 2025-01-01 2025-03-31 0000012239 2025-03-31 2025-03-31 0000012239 domh:InvestmentInAmericanBitcoinCorpMember 2025-03-31 0000012239 domh:AmericanDataCentersIncMember 2025-03-31 2025-03-31 0000012239 2025-06-27 2025-06-27 0000012239 2025-06-27 0000012239 domh:InvestmentInAmericanBitcoinCorpMember us-gaap:PrivatePlacementMember 2025-06-30 0000012239 us-gaap:CommonClassBMember 2025-01-01 2025-06-30 0000012239 us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0000012239 2025-01-01 2025-09-03 0000012239 2025-09-03 0000012239 domh:LockUpAgreementMember 2025-09-30 0000012239 domh:LockUpAgreementMember 2025-01-01 2025-09-30 0000012239 domh:InvestmentInKernaHealthIncMember 2024-12-31 0000012239 domh:InvestmentInKernaHealthIncMember 2025-09-30 0000012239 domh:InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember 2024-12-31 0000012239 domh:InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember 2025-09-30 0000012239 domh:InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember 2024-12-31 0000012239 domh:InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember 2025-09-30 0000012239 domh:InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember 2024-12-31 0000012239 domh:InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember 2025-09-30 0000012239 domh:InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember 2024-12-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember 2025-09-30 0000012239 domh:InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember 2024-12-31 0000012239 domh:InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember 2025-09-30 0000012239 domh:InvestmentInAeonPartnersFundSeriesDBDatabricksIncMember 2024-12-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesDBDatabricksIncMember 2025-09-30 0000012239 domh:InvestmentInDiscordIncMember 2024-12-31 0000012239 domh:InvestmentInDiscordIncMember 2025-09-30 0000012239 domh:InvestmentInThrasioIncMember 2024-12-31 0000012239 domh:InvestmentInThrasioIncMember 2025-09-30 0000012239 domh:InvestmentInAutomationAnywhereIncMember 2024-12-31 0000012239 domh:InvestmentInAutomationAnywhereIncMember 2025-09-30 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember 2024-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember 2025-09-30 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember 2024-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember 2025-09-30 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2024-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2025-09-30 0000012239 domh:InvestmentInAdvEnIncMember 2024-12-31 0000012239 domh:InvestmentInAdvEnIncMember 2025-09-30 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2025-01-01 2025-09-30 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2025-03-24 2025-03-24 0000012239 domh:RaefanIndustriesLLCMember 2025-01-01 2025-09-30 0000012239 domh:RaefanIndustriesLLCMember 2024-01-01 2024-12-31 0000012239 domh:AmericanInnovativeRoboticsMember 2025-01-01 2025-09-30 0000012239 domh:AmericanInnovativeRoboticsMember 2025-09-30 0000012239 domh:RaefanIndustriesLLCMember 2024-12-31 0000012239 domh:AmericanInnovativeRoboticsMember 2024-01-01 2024-12-31 0000012239 domh:AmericanInnovativeRoboticsMember 2024-12-31 0000012239 srt:ScenarioForecastMember 2025-11-30 2025-11-30 0000012239 srt:ScenarioForecastMember 2026-03-01 2026-03-01 0000012239 us-gaap:FairValueInputsLevel1Member 2025-09-30 0000012239 us-gaap:FairValueInputsLevel3Member 2025-09-30 0000012239 us-gaap:FairValueInputsLevel2Member 2025-09-30 0000012239 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-09-30 0000012239 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-09-30 0000012239 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000012239 2022-07-11 0000012239 2023-01-11 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 us-gaap:SubsequentEventMember 2025-10-01 0000012239 us-gaap:SubsequentEventMember 2025-10-01 2025-10-01 0000012239 us-gaap:SubsequentEventMember 2025-10-31 2025-10-31 0000012239 us-gaap:WarrantMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000012239 us-gaap:WarrantMember us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000012239 us-gaap:WarrantMember 2025-09-30 0000012239 us-gaap:EmployeeStockMember 2025-07-01 2025-09-30 0000012239 us-gaap:EmployeeStockMember 2025-01-01 2025-09-30 0000012239 us-gaap:ConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:RestrictedStockMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000012239 us-gaap:ConvertiblePreferredStockMember 2025-07-01 2025-09-30 0000012239 us-gaap:ConvertiblePreferredStockMember 2025-01-01 2025-09-30 0000012239 us-gaap:WarrantMember 2025-07-01 2025-09-30 0000012239 us-gaap:WarrantMember 2025-01-01 2025-09-30 0000012239 us-gaap:RestrictedStockMember 2025-07-01 2025-09-30 0000012239 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0000012239 domh:SecuritiesPurchaseAgreementsMember 2025-02-10 2025-02-10 0000012239 domh:SecuritiesPurchaseAgreementsMember 2025-02-10 0000012239 us-gaap:CommonStockMember 2025-02-10 2025-02-10 0000012239 2025-02-10 0000012239 domh:SeriesAWarrantsMember 2025-02-10 0000012239 domh:SeriesBWarrantsMember 2025-02-10 0000012239 2025-02-10 2025-02-10 0000012239 us-gaap:CommonStockMember domh:AdvisoryAgreementsMember 2025-02-18 2025-02-18 0000012239 domh:AdvisoryAgreementsMember 2025-02-10 2025-02-10 0000012239 us-gaap:CommonStockMember 2025-04-01 2025-09-30 0000012239 us-gaap:MajorityShareholderMember us-gaap:SeriesDPreferredStockMember 2013-09-30 0000012239 us-gaap:SeriesDPreferredStockMember 2013-09-30 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2025-09-30 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2024-12-31 0000012239 2025-03-03 2025-03-03 0000012239 2025-09-26 2025-09-26 0000012239 2025-01-01 2025-03-31 0000012239 domh:RestrictedStockAwardsMember domh:EquityIncentivePlanMember 2022-10-07 0000012239 domh:EquityIncentivePlanMember 2025-02-10 0000012239 domh:EquityIncentivePlanMember 2025-02-10 2025-02-10 0000012239 domh:EquityIncentivePlanMember domh:MessrChristopherDevallMember 2025-02-10 0000012239 domh:EquityIncentivePlanMember domh:MessrChristopherDevallMember 2025-02-10 2025-02-10 0000012239 domh:MessrAnthonyHayesMember 2025-02-12 2025-02-12 0000012239 domh:AnthonyHayesAndKyleWoolMember us-gaap:CommonStockMember 2025-03-11 2025-03-11 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000012239 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000012239 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000012239 domh:AnthonyHayesAndKyleWoolMember 2025-02-10 2025-02-10 0000012239 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0000012239 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000012239 domh:AVManagerMember 2025-09-30 0000012239 domh:AVInvestmentManagerMember 2025-09-30 0000012239 us-gaap:WarrantMember 2024-12-31 0000012239 us-gaap:WarrantMember 2024-01-01 2024-12-31 0000012239 us-gaap:WarrantMember 2025-01-01 2025-09-30 0000012239 us-gaap:WarrantMember 2025-09-30 0000012239 us-gaap:RestrictedStockMember 2024-12-31 0000012239 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0000012239 us-gaap:RestrictedStockMember 2025-09-30 0000012239 domh:UnderwritingMember 2025-07-01 2025-09-30 0000012239 domh:UnderwritingMember 2024-07-01 2024-09-30 0000012239 domh:UnderwritingMember 2025-01-01 2025-09-30 0000012239 domh:UnderwritingMember 2024-01-01 2024-09-30 0000012239 domh:CommissionsMember 2025-07-01 2025-09-30 0000012239 domh:CommissionsMember 2024-07-01 2024-09-30 0000012239 domh:CommissionsMember 2025-01-01 2025-09-30 0000012239 domh:CommissionsMember 2024-01-01 2024-09-30 0000012239 domh:AdvisoryFeesMember 2025-07-01 2025-09-30 0000012239 domh:AdvisoryFeesMember 2024-07-01 2024-09-30 0000012239 domh:AdvisoryFeesMember 2025-01-01 2025-09-30 0000012239 domh:AdvisoryFeesMember 2024-01-01 2024-09-30 0000012239 domh:CarriedInterestFeesMember 2025-07-01 2025-09-30 0000012239 domh:CarriedInterestFeesMember 2024-07-01 2024-09-30 0000012239 domh:CarriedInterestFeesMember 2025-01-01 2025-09-30 0000012239 domh:CarriedInterestFeesMember 2024-01-01 2024-09-30 0000012239 domh:OtherMember 2025-07-01 2025-09-30 0000012239 domh:OtherMember 2024-07-01 2024-09-30 0000012239 domh:OtherMember 2025-01-01 2025-09-30 0000012239 domh:OtherMember 2024-01-01 2024-09-30 0000012239 domh:DominariSecuritiesMember 2025-09-30 0000012239 2023-06-30 2023-06-30 0000012239 domh:RevereSecuritiesLLCMember 2025-09-30 0000012239 srt:MinimumMember 2024-01-01 2024-12-31 0000012239 srt:MaximumMember 2024-01-01 2024-12-31 0000012239 domh:NoncontrollingInterestsMember 2025-09-30 0000012239 domh:NoncontrollingInterestsMember 2025-01-01 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-07-01 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2025-07-01 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-07-01 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2024-07-01 2024-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2024-07-01 2024-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2024-07-01 2024-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2024-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2024-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2024-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-01-01 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2025-01-01 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-01-01 2025-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2024-01-01 2024-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyAIkidoPharmaMember 2024-01-01 2024-09-30 0000012239 domh:ChiefOperatingDecisionMakerMember 2024-01-01 2024-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure domh:Segments
    Get the next $DOMH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOMH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lieberman Ronald Craig bought 21,613 shares and was granted 10,000 shares (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    9/30/25 4:30:13 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ledwick Tim S bought 8,645 shares and was granted 10,000 shares, increasing direct ownership by 145% to 31,471 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    2/12/25 5:03:10 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lieberman Ronald J. bought 21,613 shares and was granted 10,000 shares (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    2/12/25 5:00:46 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dominari Securities Raises Over $1.4 Billion Year-to-Date in Support of American Innovation and Entrepreneurship

    Underscores commitment to U.S. private enterprise and technology leadership through strategic placements in leading American companies and emerging technology platforms NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Dominari Securities LLC ("Dominari Securities" or the "Company"), a principal subsidiary of Dominari Holdings Inc. (NASDAQ:DOMH), today announced that year-to-date it has raised more than $1.4 billion in capital markets activity from investors to support American companies across key sectors of innovation including artificial intelligence, defense technology, financial infrastructure and next-generation computing.

    10/16/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces Board Member Tim Ledwick to Assume Role of Interim Chief Financial Officer

    NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced that Tim Ledwick, a current member of the Company's Board of Directors, has stepped down from the Board to serve as Interim Chief Financial Officer, beginning October 1, 2025. "Tim has extensive experience leading financial operations across multiple industries," said Anthony Hayes, Chief Executive Officer of Dominari Holdings. "His background spans public and private companies, with expertise in restructuring, capital markets, M&A, and operational turnarounds. As Interim Chief Finan

    9/23/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Lieberman Ronald Craig

    3 - Dominari Holdings Inc. (0000012239) (Issuer)

    9/30/25 4:30:11 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lieberman Ronald Craig was granted 150,000 shares, increasing direct ownership by 474% to 181,613 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    9/30/25 4:30:15 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lieberman Ronald Craig bought 21,613 shares and was granted 10,000 shares (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    9/30/25 4:30:13 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    SEC Filings

    View All

    SEC Form DEF 14A filed by Dominari Holdings Inc.

    DEF 14A - Dominari Holdings Inc. (0000012239) (Filer)

    11/10/25 8:08:01 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Dominari Holdings Inc.

    10-Q - Dominari Holdings Inc. (0000012239) (Filer)

    11/10/25 8:03:42 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRER14A filed by Dominari Holdings Inc.

    PRER14A - Dominari Holdings Inc. (0000012239) (Filer)

    10/31/25 4:16:51 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

    Accomplished entrepreneur and global speaker to strengthen firm's marketing, investor engagement and strategic communications to help drive growth NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced the appointment of Brian Parsley to its Board of Directors. Parsley, an accomplished entrepreneur, behavioral analyst and internationally recognized speaker, will support the firm's growth by enhancing its marketing, investor outreach and overall communications strategy. Mr. Parsley has more than 30 years of experience in entrepreneurship,

    9/10/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Set to Join Russell Microcap® Index

    NEW YORK, May 28, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), is set to join the Russell Microcap® Index at the conclusion of the 2025 Russell indexes annual reconstitution, effective after the US market opens on June 30, according to a preliminary list of additions posted May 23. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth

    5/28/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Announces Record Date for Cash Dividend

    NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $5 million, or $0.22 per share. The dividend is expected to be payable on or around September 26, 2025, to DOMH's shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on September 3, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/ About Dominari Holdings Inc.

    8/22/25 9:15:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Marks Inflection Point with Second Quarter 2025 Financial Results

    Revenue of $34.1 Million, up 520%Closed 46 Transactions in Q2 with Total Raise Amount of More Than $288.9 Million between both our Private & Public TransactionsNEW YORK, Aug. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced financial results for the quarter that ended June 30, 2025. The results underscore a significant inflection point for the Company, which delivered breakout performance during the quarter. "This quarter marks a turning point for Dominari," said Anthony Hayes, Chief Executive Officer of Dominari Holdings. "Revenue reached $34.1 m

    8/12/25 9:15:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Investment, American Data Centers, Becomes American Bitcoin in Transformative Bitcoin Mining Deal with Hut 8

    Dominari Executing Expansion Strategy with Investment in Industrial Scale Bitcoin Mining and Bitcoin Reserve Development  NEW YORK, March 31, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced that American Data Centers Inc. ("ADC") and Hut 8 Corp, ("Hut") partnered to form American Bitcoin Corporation.  As previously announced, ADC was a wholly owned subsidiary of Dominari, but became an independent company, whose members include Donald J. Trump Jr., Eric Trump, Dominari and other industry professionals in the AI space.  In partnership with Hut, American Bitcoin Corp., will focus on industrial-scale bitcoin mining and strategic bitcoin reserve development and monetiza

    3/31/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care